arrow
A

Anna V. Tinker

bc cancer – vancouver
H指数:49
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Identifying High-Risk Relapse in Early-Stage I–II Ovarian Cancer Using the CA-125 ELIMination rate constant K (KELIM) Score: A GCIG Individual Patient Data Meta-analysis

使用CA-125 ELIMination率常数K (KELIM)评分识别早期I-II期卵巢癌的高复发风险:一项GCIG个体患者数据荟萃分析

2025-10-100
OAAI
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative

Terry Fox Research Institute马拉松希望癌症中心网络:一项全加拿大的精准肿瘤学倡议

2025-04-010
PRE
Difference Of Chemosensitivity Between Western And Japanese Women In First-Line Setting Of Advanced Serous Ovarian Cancer: Data From The MAOV Individual Patient Data Meta-Analysis

西方与日本女性在晚期浆液性卵巢癌一线治疗中的化疗敏感性差异:来自MAOV个体患者数据Meta分析的数据

2025-02-010
PRE
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first- line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
2023-09-018
OAAI
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
2023-06-0616
OAAI
Whole-genome and transcriptome analysis enhances precision cancer treatment options

全基因组和转录组分析增强了精确的癌症治疗选择

2022-09-0146
OA
Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study
2022-09-013
OAAI
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

富含DNA修复缺陷的晚期实体瘤患者CX-5461的I期CCTG IND.231试验结果

2022-06-2463
OAAI
Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas

经过验证的生物标志物检测证实,ARID1A丢失与MMR缺乏,CD8 TIL浸润混淆,并且在子宫内膜异位症相关的卵巢癌中没有独立的预后价值。

2022-02-0721
OA
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study
2022-01-21184
OAAI